The stock of aTyr Pharma Inc (NASDAQ:LIFE) is a huge mover today! About 319,115 shares traded hands or 165.88% up from the average. aTyr Pharma Inc (NASDAQ:LIFE) has declined 9.77% since April 18, 2016 and is downtrending. It has underperformed by 14.20% the S&P500.
The move comes after 7 months positive chart setup for the $92.92M company. It was reported on Nov, 18 by Barchart.com. We have $9.66 PT which if reached, will make NASDAQ:LIFE worth $149.60M more.
aTyr Pharma Inc (NASDAQ:LIFE) Ratings Coverage
Out of 4 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 25% are positive. Life Technologies Corp has been the topic of 6 analyst reports since August 25, 2015 according to StockzIntelligence Inc. Citigroup initiated the stock with “Neutral” rating in Wednesday, December 16 report. The stock has “Market Perform” rating given by William Blair on Thursday, March 31. The stock of aTyr Pharma Inc (NASDAQ:LIFE) has “Neutral” rating given on Tuesday, August 16 by Citigroup. As per Thursday, August 11, the company rating was maintained by JP Morgan. Zacks downgraded aTyr Pharma Inc (NASDAQ:LIFE) on Tuesday, August 25 to “Hold” rating. The firm earned “Sell” rating on Thursday, September 17 by Zacks.
According to Zacks Investment Research, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.”
More notable recent aTyr Pharma Inc (NASDAQ:LIFE) news were published by: Prnewswire.com which released: “aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J …” on September 21, 2016, also Prnewswire.com with their article: “aTyr Pharma Announces Third Quarter 2016 Operating Results” published on November 14, 2016, Prnewswire.com published: “aTyr Pharma Receives FDA Fast Track Designation for Resolarisâ„¢ to Treat …” on October 24, 2016. More interesting news about aTyr Pharma Inc (NASDAQ:LIFE) were released by: Prnewswire.com and their article: “aTyr Pharma Announces Presentation at the 21st International Annual Congress …” published on September 29, 2016 as well as Prnewswire.com‘s news article titled: “aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer” with publication date: January 06, 2016.
LIFE Company Profile
aTyr Pharma, Inc., incorporated on October 8, 2005, is a clinical-stage biotherapeutics company. The Firm is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Firm focuses on the development of Physiocrine therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.